Design Short Long Term Debt Total vs Retained Earnings Analysis

DSGN Stock

USD 5.76 0.04 0.69%

Design Therapeutics financial indicator trend analysis is much more than just examining Design Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Design Therapeutics is a good investment. Please check the relationship between Design Therapeutics Short Long Term Debt Total and its Retained Earnings accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Design Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.

Short Long Term Debt Total vs Retained Earnings

Short Long Term Debt Total vs Retained Earnings Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Design Therapeutics Short Long Term Debt Total account and Retained Earnings. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Design Therapeutics' Short Long Term Debt Total and Retained Earnings is -0.7. Overlapping area represents the amount of variation of Short Long Term Debt Total that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Design Therapeutics, assuming nothing else is changed. The correlation between historical values of Design Therapeutics' Short Long Term Debt Total and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt Total of Design Therapeutics are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Short Long Term Debt Total i.e., Design Therapeutics' Short Long Term Debt Total and Retained Earnings go up and down completely randomly.

Correlation Coefficient

-0.7

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Short Long Term Debt Total

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Most indicators from Design Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Design Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Design Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.As of the 19th of November 2024, Sales General And Administrative To Revenue is likely to grow to about 10.4 K, while Selling General Administrative is likely to drop about 12 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	35.8M	67.6M	78.2M	42.2M
Cost Of Revenue	129K	466K	537K	563.9K

Total Operating Expenses Cost Of Revenue

Design Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Non Current Liabilities Other	Net Working Capital	Short Term Debt	Common Stock
Total Assets		0.86	0.89	0.82	1.0	0.86	0.98	-0.43	-0.66	-0.79	-0.25	0.67	1.0	0.97	0.95	0.01	0.7	0.21	1.0	-0.43	1.0	0.98	0.95	1.0	-0.41	0.98
Short Long Term Debt Total	0.86		0.79	0.63	0.81	0.97	0.8	-0.41	-0.5	-0.7	-0.51	0.51	0.86	0.8	0.8	0.51	0.63	0.68	0.81	-0.41	0.86	0.81	0.82	0.86	-0.67	0.81
Other Current Liab	0.89	0.79		0.97	0.89	0.83	0.91	-0.52	-0.27	-0.91	-0.05	0.28	0.89	0.94	0.98	0.01	0.8	0.24	0.89	-0.52	0.89	0.95	0.92	0.89	-0.13	0.95
Total Current Liabilities	0.82	0.63	0.97		0.82	0.68	0.85	-0.48	-0.16	-0.87	0.19	0.17	0.81	0.88	0.95	-0.2	0.84	0.04	0.82	-0.48	0.81	0.89	0.85	0.81	0.08	0.89
Total Stockholder Equity	1.0	0.81	0.89	0.82		0.82	0.99	-0.42	-0.67	-0.78	-0.2	0.68	1.0	0.97	0.95	-0.07	0.7	0.13	1.0	-0.42	1.0	0.98	0.95	1.0	-0.37	0.98
Other Liab	0.86	0.97	0.83	0.68	0.82		0.82	-0.61	-0.43	-0.83	-0.5	0.43	0.86	0.83	0.84	0.43	0.58	0.63	0.82	-0.61	0.86	0.84	0.89	0.86	-0.52	0.84
Net Tangible Assets	0.98	0.8	0.91	0.85	0.99	0.82		-0.42	-0.63	-0.8	-0.23	0.63	0.98	1.0	0.96	-0.06	0.65	0.13	0.99	-0.42	0.98	0.99	0.94	0.98	-0.31	0.99
Current Deferred Revenue	-0.43	-0.41	-0.52	-0.48	-0.42	-0.61	-0.42		-0.02	0.83	0.15	0.02	-0.43	-0.45	-0.55	0.05	-0.2	-0.14	-0.42	1.0	-0.43	-0.5	-0.68	-0.43	-0.2	-0.5
Net Debt	-0.66	-0.5	-0.27	-0.16	-0.67	-0.43	-0.63	-0.02		0.15	0.49	-1.0	-0.67	-0.56	-0.41	0.01	-0.14	-0.02	-0.67	-0.02	-0.67	-0.55	-0.5	-0.67	0.67	-0.55
Retained Earnings	-0.79	-0.7	-0.91	-0.87	-0.78	-0.83	-0.8	0.83	0.15		0.12	-0.16	-0.78	-0.84	-0.91	0.03	-0.6	-0.22	-0.78	0.83	-0.78	-0.86	-0.92	-0.78	-0.04	-0.86
Accounts Payable	-0.25	-0.51	-0.05	0.19	-0.2	-0.5	-0.23	0.15	0.49	0.12		-0.49	-0.26	-0.21	-0.1	-0.68	0.34	-0.65	-0.2	0.15	-0.25	-0.21	-0.21	-0.26	0.72	-0.21
Cash	0.67	0.51	0.28	0.17	0.68	0.43	0.63	0.02	-1.0	-0.16	-0.49		0.68	0.57	0.42	-0.01	0.15	0.02	0.68	0.02	0.67	0.56	0.51	0.68	-0.66	0.56
Cash And Short Term Investments	1.0	0.86	0.89	0.81	1.0	0.86	0.98	-0.43	-0.67	-0.78	-0.26	0.68		0.97	0.95	0.01	0.7	0.21	1.0	-0.43	1.0	0.97	0.95	1.0	-0.42	0.97
Common Stock Total Equity	0.97	0.8	0.94	0.88	0.97	0.83	1.0	-0.45	-0.56	-0.84	-0.21	0.57	0.97		0.98	-0.05	0.67	0.15	0.97	-0.45	0.97	1.0	0.95	0.97	-0.27	1.0
Common Stock Shares Outstanding	0.95	0.8	0.98	0.95	0.95	0.84	0.96	-0.55	-0.41	-0.91	-0.1	0.42	0.95	0.98		-0.06	0.76	0.18	0.95	-0.55	0.95	0.98	0.97	0.94	-0.17	0.98
Non Current Liabilities Total	0.01	0.51	0.01	-0.2	-0.07	0.43	-0.06	0.05	0.01	0.03	-0.68	-0.01	0.01	-0.05	-0.06		-0.02	0.97	-0.07	0.05	0.01	-0.05	-0.03	0.02	-0.71	-0.05
Other Current Assets	0.7	0.63	0.8	0.84	0.7	0.58	0.65	-0.2	-0.14	-0.6	0.34	0.15	0.7	0.67	0.76	-0.02		0.18	0.7	-0.2	0.7	0.68	0.66	0.7	-0.14	0.68
Total Liab	0.21	0.68	0.24	0.04	0.13	0.63	0.13	-0.14	-0.02	-0.22	-0.65	0.02	0.21	0.15	0.18	0.97	0.18		0.13	-0.14	0.21	0.16	0.2	0.21	-0.69	0.16
Net Invested Capital	1.0	0.81	0.89	0.82	1.0	0.82	0.99	-0.42	-0.67	-0.78	-0.2	0.68	1.0	0.97	0.95	-0.07	0.7	0.13		-0.42	1.0	0.98	0.95	1.0	-0.36	0.98
Short Long Term Debt	-0.43	-0.41	-0.52	-0.48	-0.42	-0.61	-0.42	1.0	-0.02	0.83	0.15	0.02	-0.43	-0.45	-0.55	0.05	-0.2	-0.14	-0.42		-0.43	-0.5	-0.68	-0.43	-0.2	-0.5
Total Current Assets	1.0	0.86	0.89	0.81	1.0	0.86	0.98	-0.43	-0.67	-0.78	-0.25	0.67	1.0	0.97	0.95	0.01	0.7	0.21	1.0	-0.43		0.98	0.95	1.0	-0.41	0.98
Capital Stock	0.98	0.81	0.95	0.89	0.98	0.84	0.99	-0.5	-0.55	-0.86	-0.21	0.56	0.97	1.0	0.98	-0.05	0.68	0.16	0.98	-0.5	0.98		0.96	0.97	-0.26	1.0
Non Current Liabilities Other	0.95	0.82	0.92	0.85	0.95	0.89	0.94	-0.68	-0.5	-0.92	-0.21	0.51	0.95	0.95	0.97	-0.03	0.66	0.2	0.95	-0.68	0.95	0.96		0.95	-0.23	0.96
Net Working Capital	1.0	0.86	0.89	0.81	1.0	0.86	0.98	-0.43	-0.67	-0.78	-0.26	0.68	1.0	0.97	0.94	0.02	0.7	0.21	1.0	-0.43	1.0	0.97	0.95		-0.42	0.97
Short Term Debt	-0.41	-0.67	-0.13	0.08	-0.37	-0.52	-0.31	-0.2	0.67	-0.04	0.72	-0.66	-0.42	-0.27	-0.17	-0.71	-0.14	-0.69	-0.36	-0.2	-0.41	-0.26	-0.23	-0.42		-0.26
Common Stock	0.98	0.81	0.95	0.89	0.98	0.84	0.99	-0.5	-0.55	-0.86	-0.21	0.56	0.97	1.0	0.98	-0.05	0.68	0.16	0.98	-0.5	0.98	1.0	0.96	0.97	-0.26

Click cells to compare fundamentals

Design Therapeutics Account Relationship Matchups

Pair Trading with Design Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Design Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Design Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Design Stock

0.68	AZN	AstraZeneca PLC ADR	Pair Corr
0.61	NVS	Novartis AG ADR Sell-off Trend	Pair Corr
0.57	VALN	Valneva SE ADR	Pair Corr
0.57	OGN	Organon	Pair Corr
0.53	LLY	Eli Lilly	Pair Corr

The ability to find closely correlated positions to Design Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Design Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Design Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Design Therapeutics to buy it.

The correlation of Design Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Design Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Design Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Design Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Design Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Design Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Design Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Design Therapeutics Stock:

How To Invest In Design

Details

Is Design Stock a good investment?

Details

What is Design Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Design Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.

You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.85)

Revenue Per Share

0.001

Return On Assets

(0.14)

Return On Equity

(0.18)

The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Design Short Long Term Debt Total vs Retained Earnings Analysis

Short Long Term Debt Total vs Retained Earnings

Short Long Term Debt Total vs Retained Earnings Correlation Analysis

Correlation Coefficient

Short Long Term Debt Total

Retained Earnings

Design Therapeutics fundamental ratios Correlations

Design Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pair Trading with Design Therapeutics

Moving against Design Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity

Cash	- 1.0	Net Debt
Non Current Liabilities Other	- 0.92	Retained Earnings
Common Stock Shares Outstanding	- 0.91	Retained Earnings
Retained Earnings	- 0.91	Other Current Liab
Retained Earnings	- 0.87	Total Current Liabilities
Common Stock	- 0.86	Retained Earnings